Tuoxin Pharmaceutical: The application for the listing of the raw material drug cytidine diphosphocholine has been approved
I'm LongbridgeAI, I can summarize articles.Tuoxin Pharmaceutical's wholly-owned subsidiary, Xinxiang Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of its raw material drug, cytidine diphosphate choline. Cytidine diphosphate choline is a commonly used neuroprotective agent, primarily used to improve brain function and promote nerve repair, suitable for patients with brain injuries, cerebrovascular diseases, and neurodegenerative diseases
According to the Zhitong Finance APP, Tuoxin Pharmaceutical (301089.SZ) announced that its wholly-owned subsidiary Xinxiang Pharmaceutical Co., Ltd. (referred to as "Xinxiang Pharmaceutical") has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, which has been publicly announced on the official website of the Drug Evaluation Center of the National Medical Products Administration.
The announcement shows that phosphatidylcholine, as a commonly used neuroprotective agent and brain metabolism activator in clinical practice, has its core pharmacological effect in improving brain function and promoting nerve repair. Its clinical application scope covers patient groups with brain injuries, cerebrovascular diseases, and neurodegenerative diseases